<![CDATA[Congenital hypothyroidism is a hormonal disorder that can inhibit the cognitive and physical development of neonates. The government requires an early screening program for congenital hypothyroidism by measuring thyroid-stimulating hormone levels. Age at sampling and history of maternal use of antithyroid drugs during pregnancy may affect the test results. This study aims to provide an overview of neonatal age, history of antithyroid drug use during pregnancy, and thyroid-stimulating hormone levels in congenital hypothyroidism screening programs. A descriptive and quantitative design with secondary data from congenital hypothyroid screening papers was analyzed univariately. It also used the population from the total sampling technique, so the study sample was 1,003 neonates. Most neonates who underwent congenital hypothyroid screening sampling had normal thyroid-stimulating hormone levels, a distribution of sampling age that was by national guidelines (2-14 days), and divided per day and no history of maternal antithyroid drug use during pregnancy, the mean thyroid-stimulating hormone level in neonates screened for congenital hypothyroidism was 2.68±2.25 mU/L, 2.44±1.95 mU/L in those aged 2–14 days, and 2.68±2.25 mU/L in neonates born to mothers exposed to antithyroid drugs. These findings support the government's program in conducting comprehensive and timely early detection of congenital hypothyroidism.]]>
Copyrights © 2026
